Altimmune Announces Successful Pre-IND Meeting with FDA
June 10, 2019 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., June 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it successfully completed a pre-IND...
Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs
June 05, 2019 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., June 05, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biotechnology company, today announced that it has received additional patent protection for its...
Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update
May 14, 2019 16:15 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., May 14, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the first quarter ended March...
Altimmune to Announce First Quarter 2019 Financial Results on May 15
May 08, 2019 08:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., May 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first...
Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
April 11, 2019 09:27 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., April 11, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced an oral presentation at the World Vaccine Congress...
Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update
April 01, 2019 16:20 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., April 01, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December 31,...
Altimmune to Announce Year End 2018 Financial Results on April 2
March 21, 2019 16:15 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., March 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the year...
Altimmune Announces Positive Results from NasoVAX Extension Study
March 19, 2019 07:00 ET
|
Altimmune, Inc.
Seroprotective HAI antibody response persisted more than one year after vaccination Company seeking partnership for further development and commercialization of NasoVAX GAITHERSBURG, Md., March 19,...
Altimmune to Participate at 31st Annual ROTH Conference
March 14, 2019 09:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., March 14, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Vipin K. Garg, Ph.D., President and Chief...
Altimmune Announces Closing of $14 Million Registered Direct Offering
March 12, 2019 13:34 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., March 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered...